S

Sonnet BioTherapeutics Holdings
D

SONN

1.39000
USD
-0.04
(-2.80%)
مغلق
حجم التداول
15,579
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
4,261,324
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABT
    ABT
    1.785
    (1.34%)
    134.950 USD
    D
    DGX
    0.115
    (0.07%)
    172.290 USD
    H
    HOLX
    0.180
    (0.28%)
    64.510 USD
    IDXX
    IDXX
    -0.33
    (-0.07%)
    452.66 USD
    P
    PACB
    -0.11000
    (-6.71%)
    1.53000 USD
    T
    TMDX
    -3.591
    (-4.76%)
    71.869 USD
    TMO
    TMO
    -5.71
    (-1.06%)
    532.28 USD
    V
    VEEV
    -2.960
    (-1.29%)
    225.900 USD
    المزيد
الأخبار
المقالات

العنوان: Sonnet BioTherapeutics Holdings Inc

القطاع: Healthcare
الصناعة: Biotechnology
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.